You are viewing the site in preview mode

Skip to main content

Table 1 (Abstract O5). Clinical data

From: 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Pt Age Disease Prior Tx BATS (x 109) TTP (mo) OS (mo) Comments
IT20087 58 Mets to liver Folfirinox 47 6 mo Died 13.6 mo Progressed after Immunotherapy
IT20091 63 T3 N1Mets to liver. S/P Whipple 5FU, Leu/5FU Folfirinox 9 79 4.8 mo Died 31 mo Folfirinox induced CR after IT and responded a 2nd time to Folfirinox
IT20092 64 T2b Abd Nodes, S/P Whipple Gemzar, 5FU, radiation 36 7 mo Died 14.5 mo Slowly progress with chronic diarrhea
IT20102 56 T4, Mets to liver, lungs Folfirinox 74 6.5 mo Alive 24.9 mo Progressed after 6.5 mo
IT20104 51 T4, Abd Node FOLFOX, X eloda 72 2.2 mo Alive 23.3 mo Chemo Induced CR after IT; On Xeloda